ABBV AbbVie Inc.
Pharmaceutical Preparations · NYSE · SEC CIK 1551152 · Fiscal year ends 12/31
Financial factors as of 2025-12-31 (2025Q4), TTM = sum of the last four quarters
Growth
TTM revenue YoY8.6%
TTM net income YoY-1.2%
TTM EPS YoY-1.3%
Revenue 3-yr CAGR1.8%
Net income 3-yr CAGR-29.1%
Margins
Gross margin70.2%
Operating margin24.6%
Net margin6.9%
FCF margin29.1%
EBITDA margin25.9%
Returns
ROE15,367.3%
ROA3.1%
ROIC (approx.)17.4%
Asset turnover0.45x
Leverage & solvency
Liabilities / assets102.4%
Debt / equity—
Current ratio0.67x
Interest coverage5.21x
Cash quality & payout
Operating cash flow / net income4.50x
Accruals ratio-11.0%
Payout ratio275.8%
Capex / revenue2.0%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 |
|---|---|---|
| Income statement | ||
| Revenue | $61.16B | $56.33B |
| Cost of revenue | $18.20B | $16.90B |
| Gross profit | $42.96B | $39.43B |
| R&D expense | $9.10B | $12.79B |
| SG&A expense | $14.01B | $14.75B |
| Operating income | $15.07B | $9.14B |
| Interest expense | $2.89B | $2.81B |
| Pretax income | $6.60B | $3.72B |
| Income tax | $2.36B | -$570.00M |
| Net income | $4.23B | $4.28B |
| EBITDA | $15.84B | $9.90B |
| EPS (basic) | 2.37 | 2.40 |
| EPS (diluted) | 2.36 | 2.39 |
| Dividends declared per share | 6.65 | 6.29 |
| Weighted avg. shares (diluted) | 1.77B | 1.77B |
| Balance sheet | ||
| Cash & equivalents | $5.23B | $5.52B |
| Short-term investments | $28.00M | $31.00M |
| Receivables | $12.59B | $10.92B |
| Inventory | $4.95B | $4.18B |
| Current assets | $29.06B | $25.58B |
| PP&E, net | $5.63B | $5.13B |
| Goodwill | $35.64B | $34.96B |
| Intangibles | $52.64B | $60.07B |
| Total assets | $133.96B | $135.16B |
| Current liabilities | $43.29B | $38.75B |
| Short-term debt | $2.50B | $0 |
| Long-term debt | $58.94B | $60.34B |
| Total debt | $61.44B | $60.34B |
| Total liabilities | $137.19B | $131.80B |
| Shareholders' equity | -$3.27B | $3.33B |
| Net debt | $56.21B | $54.82B |
| Cash flow statement | ||
| Operating cash flow | $19.03B | $18.81B |
| Capital expenditure | $1.21B | $974.00M |
| Free cash flow | $17.82B | $17.83B |
| Investing cash flow | -$6.64B | -$20.82B |
| Financing cash flow | -$12.72B | -$5.21B |
| Depreciation & amortization | $762.00M | $764.00M |
| Stock-based compensation | $955.00M | $911.00M |
| Dividends paid | $11.66B | $11.03B |
| Share buybacks | $980.00M | $1.71B |
Free plan shows the latest 2 periods; Pro shows all 15 🔒
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.